The customer received questionable elecsys ft4 ii assay results for one patient sample when compared to the result from an abbott analyzer.The customer used a cobas 6000 e 601 module serial number (b)(4).On (b)(6) 2017, the ft4 result for the patient was elevated (41 pmol/l) with a tsh result of 0.81 mu/l.Based on these results, the medical personnel started treating the patient with strumazol.On (b)(6) 2017, a new sample was drawn and the results showed that the ft4 was not significantly dropping (37 pmol/l).Therefore, the result was questioned and the same sample was retested using an abbott system.As the abbott ft4 result was different (14 pmol/l) the strumazol treatment was halted.The abbott results are viewed as the correct results by the customer.There was no allegation of an adverse event.A specific root cause could not be identified.As no sample from the patient was available, further investigation was not possible.From the information provided, a general reagent issue could most likely be excluded.Based on the data provided, an interfering factor may be present in the samples that either affects the ft4 assay from either manufacturer.
|